Trial Profile
Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jun 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Hepatitis B; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 15 Dec 2016 New trial record